KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Acadia Pharmaceuticals (ACAD) over the last 15 years, with Sep 2025 value amounting to $27.8 million.

  • Acadia Pharmaceuticals' Change in Accured Expenses rose 109.76% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.9 million, marking a year-over-year increase of 1.89%. This contributed to the annual value of $71.1 million for FY2024, which is 23.73% down from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Change in Accured Expenses stood at $27.8 million, which was up 42.86% from $19.4 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Change in Accured Expenses peaked at $38.1 million during Q4 2023, and registered a low of -$14.1 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was $19.4 million (2025), whereas its average is $19.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 198.82% in 2021, then surged by 2,971.10% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $8.8 million in 2021, then dropped by 25.78% to $6.5 million in 2022, then surged by 483.52% to $38.1 million in 2023, then fell by 19.29% to $30.8 million in 2024, then soared by 109.76% to $27.8 million in 2025.
  • Its Change in Accured Expenses stands at $27.8 million for Q3 2025, versus $19.4 million for Q2 2025 and $1.9 million for Q1 2025.